EcoDrugPlus

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSPCTG00005017268
Gene Symbol: ERBB3
3 Cross references
282 Possible Orthologues:

Exportin 1

Ensembl ID : ENSPCTG00005006261
Gene Symbol: XPO1
3 Cross references
304 Possible Orthologues:

Farnesyl Diphosphate Synthase

Ensembl ID : ENSPCTG00005019548
Gene Symbol: FDPS
1 Cross references
262 Possible Orthologues:

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSPCTG00005019224
Gene Symbol: FDFT1
1 Cross references
214 Possible Orthologues:

Fibroblast Growth Factor Receptor 1

Ensembl ID : ENSPCTG00005015429
Gene Symbol: FGFR1
3 Cross references
289 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSPCTG00005022152
Gene Symbol: FGFR2
1 Cross references
216 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSPCTG00005006670
Gene Symbol: FGFR3
1 Cross references
196 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 3

Ensembl ID : ENSPCTG00005013790
Gene Symbol: FLT3
1 Cross references
133 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSPCTG00005000690
Gene Symbol: FLT4
3 Cross references
195 Possible Orthologues:

Fms Related Tyrosine Kinase 1

Ensembl ID : ENSPCTG00005014294
Gene Symbol: FLT1
3 Cross references
198 Possible Orthologues:

Folate Hydrolase 1b

Ensembl ID : ENSPCTG00005006376
Gene Symbol: FOLH1B
3 Cross references
210 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSPCTG00005014365
Gene Symbol: FSHR
3 Cross references
199 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).